Safety of biologic therapies - An update

被引：0
|
作者：
Keystone, EC
机构：
[1] Mt Sinai Hosp, Rebecca MacDonald Ctr Arthrit & Autoimmune Dis, Div Adv Therapeut, Toronto, ON M5G 1X5, Canada
[2] Univ Toronto, Toronto, ON, Canada
[3] Div Adv Therapeut, Toronto, ON, Canada
来源：
JOURNAL OF RHEUMATOLOGY | 2005年 / 32卷
关键词：
biologic therapies; rheumatoid arthritis; safety; clinical trials;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Tumor necrosis factor (TNF) antagonists have set a new therapeutic standard for rheumatoid arthritis (RA). Agents including infliximab, etanercept, and adalimumab have demonstrated substantial improvement in signs and symptoms, disability, and quality of life, while significantly inhibiting joint damage in early and long-standing RA. Safety issues in concert with efficacy determine risk/benefit ratio and hence a position in the therapeutic algorithm. This brief review focuses on infection, congestive heart, and malignancy.
引用
收藏
页码：8 / 12
页数：5
相关论文
共 50 条
  • [31] Biologic therapies in autoimmune diseases
    Penn, H
    CLINICAL MEDICINE, 2006, 6 (01) : 105 - 108
  • [32] Biologic and New Therapies in Asthma
    Tabatabaian, Farnaz
    Ledford, Dennis K.
    Casale, Thomas B.
    IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2017, 37 (02) : 329 - +
  • [33] Malignancy Risks With Biologic Therapies
    Cush, John J.
    Dao, Kathryn H.
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2012, 38 (04) : 761 - +
  • [34] The Role of Biologic Therapies in Dermatology
    Fathi, Ramin
    Armstrong, April Wang
    MEDICAL CLINICS OF NORTH AMERICA, 2015, 99 (06) : 1183 - +
  • [35] Biologic therapies in the treatment of psoriasis
    Farhi, David
    Dupin, Nicolas
    PRESSE MEDICALE, 2009, 38 (05): : 832 - 843
  • [36] Biologic therapies for psoriasis and eyes
    Burek-Michalska, Alicja
    Turno-Krecicka, Anna
    Grant-Kels, Jane M.
    Grzybowski, Andrzej
    CLINICS IN DERMATOLOGY, 2023, 41 (04) : 523 - 527
  • [37] A systematic literature review of efficacy, effectiveness and safety of biologic therapies for treatment of familial Mediterranean fever
    Kuemmerle-Deschner, Jasmin B.
    Gautam, Raju
    George, Aneesh T.
    Raza, Syed
    Lomax, Kathleen G.
    Hur, Peter
    RHEUMATOLOGY, 2020, 59 (10) : 2711 - 2724
  • [38] Biologic therapies for systemic lupus erythematosus: where are we now?
    Murphy, Grainne
    Isenberg, David A.
    CURRENT OPINION IN RHEUMATOLOGY, 2020, 32 (06) : 597 - 608
  • [39] Access to Biologic Therapies in Canada for Children with Juvenile Idiopathic Arthritis
    LeBlanc, Claire M. A.
    Lang, Bianca
    Bencivenga, Alma
    Chetaille, Anne-Laure
    Dancey, Paul
    Dent, Peter
    Miettunen, Paivi
    Oen, Kiem
    Rosenberg, Alan
    Roth, Johannes
    Scuccimarri, Rosie
    Tse, Shirley M. L.
    Benseler, Susanne
    Cabral, David A.
    Campillo, Sarah
    Chedeville, Gaelle
    Duffy, Ciaran M.
    Duffy, Karen Watanabe
    Haddad, Elie
    Huber, Adam M.
    Laxer, Ronald
    Levy, Deborah
    Johnson, Nicole
    Ramsey, Suzanne
    Shiff, Natalie
    Schmeling, Heinrike
    Schneider, Rayfel
    Stringer, Elizabeth
    Yeung, Rae S. M.
    Tucker, Lori B.
    JOURNAL OF RHEUMATOLOGY, 2012, 39 (09) : 1875 - 1879
  • [40] When is switching warranted among biologic therapies in rheumatoid arthritis?
    Reynolds, Alan
    Koenig, Andrew S.
    Bananis, Eustratios
    Singh, Amitabh
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2012, 12 (03) : 319 - 333
12345